| abstract |
The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, in particular pemphigus bullosa (BP) and chronic spontaneous urticaria (CSU). Anti-IgE antibodies comprise a variant Fc domain that binds the Fc receptor FcRn with increased affinity compared to the wild-type Fc domain. The anti-IgE antibody may comprise a variant Fc domain comprising amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain is wild-type Binds to human FcRn with increased affinity compared to the human IgG Fc domain. |